Herbalife Toekomstige groei
Future criteriumcontroles 2/6
Herbalife zal naar verwachting groeien in winst en omzet met respectievelijk 15.8% en 3.2% per jaar. De winst per aandeel zal naar verwachting groeien met 13.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 1731.4% zijn.
Belangrijke informatie
15.8%
Groei van de winst
13.69%
Groei van de winst per aandeel
| Personal Products winstgroei | 33.1% |
| Inkomstengroei | 3.2% |
| Toekomstig rendement op eigen vermogen | 1,731.39% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 13 May 2026 |
Recente toekomstige groei-updates
Recent updates
Analyseartikel • May 19
Investors Can Find Comfort In Herbalife's (NYSE:HLF) Earnings Quality
Investors were disappointed with the weak earnings posted by Herbalife Ltd. ( NYSE:HLF ). However, our analysis...Seeking Alpha • May 11
Herbalife: The Stock Wall Street Loves To Hate Is Making A Comeback
Summary Herbalife is undergoing a significant transformation, shifting from its traditional multi-level marketing model to a modern health and wellness brand. HLF is leveraging biomarker-driven personalization, direct digital health engagement, and strategic acquisitions like Bioniq and Pro2col to diversify its offerings. Recent debt refinancing and ongoing reductions have improved HLF's financial profile, with debt falling from ~$3.0B in 2021 to ~$2.18B in 2025. Wall Street has largely discounted HLF's transformation, overlooking its established brand, cash flow, and loyal customer base supporting its strategic pivot. Read the full article on Seeking Alpha
Narratiefupdate • May 05
HLF: Mixed 2026 Guidance And Execution Outlook Will Shape Turnaround Prospects
Herbalife's analyst price target has been revised higher to $17.50 from $16.50, with analysts pointing to updated fair value assumptions and recent target increases at firms such as Citi, BofA and Mizuho following Q4 results and 2026 guidance. Analyst Commentary Recent research updates show a mix of optimism and caution around Herbalife, with price targets moving in different directions as analysts react to Q4 results, 2026 guidance and updated assumptions around execution and valuation.
Narratiefupdate • Apr 20
HLF: 2026 Guidance And Margin Recovery Will Drive Turnaround Momentum
Analysts lifted their price targets for Herbalife by as much as $4, with some pointing to Q4 results that were largely in line, fresh 2026 guidance, and what they view as stronger recent momentum as key factors behind the adjustment. Analyst Commentary Bullish analysts are highlighting recent price target increases on Herbalife as a sign of improving confidence in the story, especially after Q4 results that were described as largely in line and supported by new 2026 guidance.Narratiefupdate • Apr 06
HLF: Turnaround Momentum And Q1 2026 Outlook Will Support Margin Recovery
Herbalife's updated analyst price target has moved from $14.00 to $16.50 as analysts factor in recent target increases, slightly higher projected revenue growth and margins, and a modestly lower discount rate, alongside updated views on valuation multiples. Analyst Commentary Recent research views on Herbalife show a mix of optimism about a potential turnaround and caution about the broader sector and the company’s fundamentals.
Narratiefupdate • Mar 23
HLF: 2026 Turnaround Ambitions Will Face Ongoing Competitive And Fundamental Pressures
Herbalife's analyst price target has shifted toward $9.00, with recent research citing Q4 results viewed as solid by some firms, new 2026 guidance, and mixed views on valuation and competitive pressures. Some analysts also commented that regulatory concerns in the U.S. are considered resolved and the business model more sustainable.Narratiefupdate • Mar 09
HLF: 2026 Turnaround Hopes Will Confront Persistent Competitive And Fundamental Risks
The analyst price target for Herbalife has been raised by $1 to $9. Analysts point to largely in line Q4 results, new 2026 guidance, and a mix of Buy, Neutral, and Underperform views that reflect both perceived momentum and ongoing concerns around competition, fundamentals, and valuation.Narratiefupdate • Feb 23
HLF: Turnaround Will Be Driven By 2026 Guidance And Margin Recovery
Narrative Update: Herbalife The updated analyst fair value estimate for Herbalife has moved from $11 to $25, a shift analysts link to refreshed price targets in the $9 to $21 range, stronger Q4 commentary, improved margin assumptions, and a lower discount rate despite mixed views on long term growth and valuation risks. Analyst Commentary Recent Street research on Herbalife reflects a mix of views, but several bullish analysts have been willing to raise price targets or upgrade their stance following recent updates from the company.Narratiefupdate • Feb 08
HLF: Turnaround Hopes Under New Leadership Will Confront Compressed Sector Multiples
Narrative Update: Herbalife Analyst Price Target Move The blended analyst price target for Herbalife has moved higher, with recent increases such as Mizuho's lift to $13 and Maxim's initiation at $20. Analysts point to an ongoing turnaround, progress under new leadership, and a healthier long term profile for Herbalife's business model, while also noting continuing concerns about competition and broader macro uncertainty.Narratiefupdate • Jan 25
HLF: Recovery Story Under New Leadership Will Face Compressed Sector Multiples
Narrative Update on Herbalife The analyst price target for Herbalife has been revised higher to reflect an updated fair value of $8.00, a lower discount rate of 10.02%, and adjustments to revenue growth, profit margin, and future P/E assumptions, as analysts factor in recent target hikes, Buy initiations, and views of a continuing recovery path under new leadership. Analyst Commentary Recent Street research on Herbalife reflects a mix of optimism about a potential recovery and caution around execution and valuation risks.Analyseartikel • Jan 22
Herbalife Ltd. (NYSE:HLF) Shares Fly 27% But Investors Aren't Buying For Growth
Herbalife Ltd. ( NYSE:HLF ) shares have continued their recent momentum with a 27% gain in the last month alone. The...Narratiefupdate • Jan 11
HLF: Turnaround And Margin Recovery Under New Leadership Will Face Valuation Constraints
The analyst price target on Herbalife in our model has moved from US$12 to US$14, as analysts point to a recovery path supported by a healthier profit margin outlook, a slightly lower discount rate, and recent research highlighting ongoing business model improvements despite tempered revenue growth expectations and cautious sector valuations. Analyst Commentary Recent research on Herbalife reflects a mix of optimism about the company’s turnaround efforts and caution about broader sector and macro headwinds.Narratiefupdate • Dec 25
HLF: Recovery Path Under New Leadership Will Likely Deliver Disappointing Multiple Expansion
Analysts have modestly raised their fair value estimate for Herbalife from approximately $9.67 to $12.00 per share, citing a lower perceived risk profile, steady growth and margin assumptions, and a more constructive view on future earnings multiples as fundamentals continue on a recovery path under new leadership. Analyst Commentary Analyst sentiment around Herbalife is gradually improving as execution under new leadership gains traction and forward growth expectations firm up, though views on the pace and durability of the recovery remain mixed.Narratiefupdate • Dec 11
HLF: Recovery Path Under New Leadership Will Likely Prove Overpriced
Analysts have modestly raised their price target on Herbalife to $11 from $10, citing a gradually lower perceived risk profile, steady long term growth and margin assumptions, and growing confidence that the company is on a recovery path under new leadership, with a potential return to volume growth by fiscal 2026. Analyst Commentary Bullish analysts point to the recent rating upgrade and price target increase as evidence that sentiment around Herbalife is gradually improving, with expectations that operational execution will support a more favorable risk and reward profile over the next several years.Narratiefupdate • Nov 27
HLF: Uncertainty Around CEO Transition Will Challenge Near-Term Momentum
Herbalife’s analyst price target has been raised to $11 from $10, as analysts point to recovering fundamentals and the company’s strategic leadership changes as promising signs for future growth. Analyst Commentary Analysts have recently weighed in on Herbalife, offering a mix of optimism about its improving fundamentals and some caution about ongoing risks.Analyseartikel • Nov 13
We Think That There Are Some Issues For Herbalife (NYSE:HLF) Beyond Its Promising Earnings
The market for Herbalife Ltd.'s ( NYSE:HLF ) stock was strong after it released a healthy earnings report last week...Analyseartikel • Oct 29
The Market Doesn't Like What It Sees From Herbalife Ltd.'s (NYSE:HLF) Earnings Yet
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Analyseartikel • Sep 26
At US$8.75, Is Herbalife Ltd. (NYSE:HLF) Worth Looking At Closely?
Herbalife Ltd. ( NYSE:HLF ), might not be a large cap stock, but it saw a decent share price growth of 11% on the NYSE...Analyseartikel • Jul 24
A Look At The Intrinsic Value Of Herbalife Ltd. (NYSE:HLF)
Key Insights The projected fair value for Herbalife is US$9.20 based on 2 Stage Free Cash Flow to Equity Herbalife's...Analyseartikel • Jun 25
There's No Escaping Herbalife Ltd.'s (NYSE:HLF) Muted Earnings Despite A 26% Share Price Rise
Those holding Herbalife Ltd. ( NYSE:HLF ) shares would be relieved that the share price has rebounded 26% in the last...Analyseartikel • May 28
Herbalife (NYSE:HLF) Hasn't Managed To Accelerate Its Returns
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analyseartikel • May 08
Herbalife's (NYSE:HLF) Earnings Offer More Than Meets The Eye
Herbalife Ltd.'s ( NYSE:HLF ) solid earnings announcement recently didn't do much to the stock price. We did some...Analyseartikel • Mar 13
Herbalife Ltd.'s (NYSE:HLF) Share Price Boosted 63% But Its Business Prospects Need A Lift Too
Herbalife Ltd. ( NYSE:HLF ) shares have had a really impressive month, gaining 63% after a shaky period beforehand. But...Seeking Alpha • Feb 24
Herbalife: The Battleground Stock Is Showing Some Turnaround Potential
Summary Herbalife still operates in 95 countries using a direct selling and MLM model with six million independent distributors. Currently, HLF is facing declining sales volumes, which have been partly offset by price increases. However, it remains uncertain how sustainable this is in the long run. Post-FTC settlement, I think HLF has “sanitized” its business model, even though it has indeed made it more challenging to grow its MLM business. The good news is its focus. They have a mixed regional performance, in particular with China struggling while Asia Pacific stabilizes. Additionally, its recruitment and sales leaders numbers have been encouraging in Q4 and 2024. Based on EV/EBITDA metrics, HLF is undeniably still priced at a steep discount. However, at this point, I believe the risk-reward equation is more favorable for the bulls. Hence, I rate it a speculative “Buy” for the short term. Read the full article on Seeking AlphaAnalyseartikel • Feb 19
Is It Time To Consider Buying Herbalife Ltd. (NYSE:HLF)?
While Herbalife Ltd. ( NYSE:HLF ) might not have the largest market cap around , it saw a double-digit share price rise...Analyseartikel • Jan 29
Returns At Herbalife (NYSE:HLF) Appear To Be Weighed Down
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Firstly, we'll want...Seeking Alpha • Jan 21
Herbalife: Down In The Dumps, But Maybe Worth Exploring
Summary Herbalife (HLF) which offers health and wellness products across the globe has underperformed other small-caps and consumer staple stocks, while witnessing almost a 50% contraction in price over the past year. The new Chief Strategy Officer has helped revive new distributor growth after years of decline, but sales growth remains stagnant, and the outlook on the topline doesn't look too alluring. While the topline is not at full tilt, HLF's restructuring efforts are leading to a great deal of savings ($130m of aggregate savings through 2025) resulting in decent EBITDA growth. The stock is attractively priced at 4x EBITDA and an FCF yield of 27%. HLF is yet to show signs of bottom formation, although the risk-reward equation within its long-term descending channel looks favorable. Read the full article on Seeking AlphaAnalyseartikel • Nov 12
Investors Still Aren't Entirely Convinced By Herbalife Ltd.'s (NYSE:HLF) Earnings Despite 27% Price Jump
Herbalife Ltd. ( NYSE:HLF ) shares have had a really impressive month, gaining 27% after a shaky period beforehand. Not...Analyseartikel • Nov 06
We Think You Can Look Beyond Herbalife's (NYSE:HLF) Lackluster Earnings
Herbalife Ltd.'s ( NYSE:HLF ) stock was strong despite it releasing a soft earnings report last week. However, we think...Seeking Alpha • Nov 05
Herbalife: A Top Short Squeeze Idea, Turning Higher In Price
Summary Herbalife is trading near a 20-year low valuation in October 2024. Earnings have beaten expectations for 3 consecutive quarters and are projected to grow by 20% annually in 2025-26. A large short interest position may be stuck, meaning any covering (buying shares) will push the share price straight up. Something of a price breakout has appeared on the daily chart pattern over the past week. Read the full article on Seeking AlphaAnalyseartikel • Nov 01
What Does Herbalife Ltd.'s (NYSE:HLF) Share Price Indicate?
Herbalife Ltd. ( NYSE:HLF ), is not the largest company out there, but it saw a decent share price growth of 12% on the...Seeking Alpha • Oct 03
Herbalife: The Biggest Value Trap Of The Moment
Summary Herbalife's products lack scientific backing, are highly processed, and fail to improve consumer health, leading to stalled growth and brand credibility issues. The MLM business model does not convince the market, undermining the long-term trust and credibility of the brand, despite appearing undervalued based on valuation multiples. Without drastic changes in product quality and business model, Herbalife is likely to face a gradual decline, as evidenced by stagnant financial performance. Read the full article on Seeking AlphaWinst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2028 | 5,597 | N/A | N/A | N/A | 1 |
| 12/31/2027 | 5,426 | 311 | N/A | 462 | 4 |
| 12/31/2026 | 5,249 | 246 | N/A | 414 | 4 |
| 3/31/2026 | 5,133 | 240 | 374 | 447 | N/A |
| 12/31/2025 | 5,038 | 228 | 253 | 333 | N/A |
| 9/30/2025 | 4,962 | 321 | 217 | 305 | N/A |
| 6/30/2025 | 4,929 | 325 | 171 | 265 | N/A |
| 3/31/2025 | 4,951 | 280 | 164 | 272 | N/A |
| 12/31/2024 | 4,993 | 254 | 163 | 285 | N/A |
| 9/30/2024 | 5,001 | 87 | 180 | 312 | N/A |
| 6/30/2024 | 5,042 | 82 | 156 | 292 | N/A |
| 3/31/2024 | 5,075 | 137 | 188 | 325 | N/A |
| 12/31/2023 | 5,062 | 142 | 223 | 358 | N/A |
| 9/30/2023 | 5,028 | 186 | 173 | 315 | N/A |
| 6/30/2023 | 5,042 | 226 | 156 | 305 | N/A |
| 3/31/2023 | 5,121 | 252 | 123 | 268 | N/A |
| 12/31/2022 | 5,204 | 321 | 196 | 353 | N/A |
| 9/30/2022 | 5,342 | 305 | 224 | 384 | N/A |
| 6/30/2022 | 5,477 | 340 | 244 | 403 | N/A |
| 3/31/2022 | 5,637 | 398 | 321 | 481 | N/A |
| 12/31/2021 | 5,803 | 447 | 309 | 460 | N/A |
| 9/30/2021 | 5,896 | 483 | 347 | 487 | N/A |
| 6/30/2021 | 5,986 | 504 | 400 | 531 | N/A |
| 3/31/2021 | 5,781 | 474 | 476 | 597 | N/A |
| 12/31/2020 | 5,542 | 373 | 517 | 629 | N/A |
| 9/30/2020 | 5,351 | 356 | 571 | 673 | N/A |
| 6/30/2020 | 5,074 | 299 | 624 | 728 | N/A |
| 3/31/2020 | 4,967 | 260 | 457 | 561 | N/A |
| 12/31/2019 | 4,877 | 311 | N/A | 458 | N/A |
| 9/30/2019 | 4,843 | 303 | N/A | 440 | N/A |
| 6/30/2019 | 4,842 | 293 | N/A | 418 | N/A |
| 3/31/2019 | 4,887 | 311 | N/A | 531 | N/A |
| 12/31/2018 | 4,892 | 297 | N/A | 648 | N/A |
| 9/30/2018 | 4,799 | 184 | N/A | 696 | N/A |
| 6/30/2018 | 4,641 | 168 | N/A | 659 | N/A |
| 3/31/2018 | 4,503 | 211 | N/A | 572 | N/A |
| 12/31/2017 | 4,428 | 214 | N/A | 591 | N/A |
| 9/30/2017 | 4,379 | 377 | N/A | 522 | N/A |
| 6/30/2017 | 4,416 | 410 | N/A | 276 | N/A |
| 3/31/2017 | 4,471 | 249 | N/A | 402 | N/A |
| 12/31/2016 | 4,488 | 260 | N/A | 367 | N/A |
| 9/30/2016 | 4,542 | 245 | N/A | 385 | N/A |
| 6/30/2016 | 4,523 | 251 | N/A | 638 | N/A |
| 3/31/2016 | 4,483 | 357 | N/A | 609 | N/A |
| 12/31/2015 | 4,469 | 339 | N/A | 629 | N/A |
| 9/30/2015 | 4,504 | 358 | N/A | 555 | N/A |
| 6/30/2015 | 4,658 | 276 | N/A | 523 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei HLF ( 15.8% per jaar) ligt boven de spaarquote ( 3.5% ).
Winst versus markt: De winst van HLF ( 15.8% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 16.8% per jaar).
Hoge groeiwinsten: De winst van HLF zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van HLF ( 3.2% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 11.7% per jaar).
Hoge groei-inkomsten: De omzet van HLF ( 3.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen HLF zal naar verwachting over 3 jaar zeer hoog zijn ( 1731.4 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 13:38 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Herbalife Ltd. wordt gevolgd door 16 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| John Staszak | Argus Research Company |
| Meredith Adler | Barclays |
| Brian Wang | Barclays |